ArticleTranslational cancer research2019

Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies.

Andrea De Giglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.